These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 16569864)

  • 1. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies.
    Bonelli RR; Schneider T; Sahl HG; Wiedemann I
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1449-57. PubMed ID: 16569864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membrane lipids determine the antibiotic activity of the lantibiotic gallidermin.
    Christ K; Al-Kaddah S; Wiedemann I; Rattay B; Sahl HG; Bendas G
    J Membr Biol; 2008; 226(1-3):9-16. PubMed ID: 19009315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors.
    Müller A; Ulm H; Reder-Christ K; Sahl HG; Schneider T
    Microb Drug Resist; 2012 Jun; 18(3):261-70. PubMed ID: 22432708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II.
    Wiedemann I; Böttiger T; Bonelli RR; Wiese A; Hagge SO; Gutsmann T; Seydel U; Deegan L; Hill C; Ross P; Sahl HG
    Mol Microbiol; 2006 Jul; 61(2):285-96. PubMed ID: 16771847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial mechanism of lantibiotics.
    Islam MR; Nagao J; Zendo T; Sonomoto K
    Biochem Soc Trans; 2012 Dec; 40(6):1528-33. PubMed ID: 23176511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid II-based antimicrobial activity of the lantibiotic plantaricin C.
    Wiedemann I; Böttiger T; Bonelli RR; Schneider T; Sahl HG; Martínez B
    Appl Environ Microbiol; 2006 Apr; 72(4):2809-14. PubMed ID: 16597986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo cluster formation of nisin and lipid II is correlated with membrane depolarization.
    Tol MB; Morales Angeles D; Scheffers DJ
    Antimicrob Agents Chemother; 2015; 59(6):3683-6. PubMed ID: 25870072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic response of Bacillus subtilis to lantibiotics reflects differences in interaction with the cytoplasmic membrane.
    Wenzel M; Kohl B; Münch D; Raatschen N; Albada HB; Hamoen L; Metzler-Nolte N; Sahl HG; Bandow JE
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5749-57. PubMed ID: 22926563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A lesson in efficient killing from two-component lantibiotics.
    Breukink E
    Mol Microbiol; 2006 Jul; 61(2):271-3. PubMed ID: 16771845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Dynamics Insight into the Lipid II Recognition by Type A Lantibiotics: Nisin, Epidermin, and Gallidermin.
    Panina I; Taldaev A; Efremov R; Chugunov A
    Micromachines (Basel); 2021 Sep; 12(10):. PubMed ID: 34683220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual role of GdmH in producer immunity and secretion of the Staphylococcal lantibiotics gallidermin and epidermin.
    Hille M; Kies S; Götz F; Peschel A
    Appl Environ Microbiol; 2001 Mar; 67(3):1380-3. PubMed ID: 11229936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttranslationally modified bacteriocins--the lantibiotics.
    Guder A; Wiedemann I; Sahl HG
    Biopolymers; 2000; 55(1):62-73. PubMed ID: 10931442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circumventing the effect of product toxicity: development of a novel two-stage production process for the lantibiotic gallidermin.
    Valsesia G; Medaglia G; Held M; Minas W; Panke S
    Appl Environ Microbiol; 2007 Mar; 73(5):1635-45. PubMed ID: 17194841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics.
    Brötz H; Josten M; Wiedemann I; Schneider U; Götz F; Bierbaum G; Sahl HG
    Mol Microbiol; 1998 Oct; 30(2):317-27. PubMed ID: 9791177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtiter plate bioassay to monitor the interference of antibiotics with the lipid II cycle essential for peptidoglycan biosynthesis.
    Burkard M; Stein T
    J Microbiol Methods; 2008 Sep; 75(1):70-4. PubMed ID: 18558445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of lipid II and membrane thickness in the mechanism of action of the lantibiotic bovicin HC5.
    Paiva AD; Breukink E; Mantovani HC
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5284-93. PubMed ID: 21876041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations.
    Morgan SM; O'connor PM; Cotter PD; Ross RP; Hill C
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2606-11. PubMed ID: 15980326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II.
    Hasper HE; Kramer NE; Smith JL; Hillman JD; Zachariah C; Kuipers OP; de Kruijff B; Breukink E
    Science; 2006 Sep; 313(5793):1636-7. PubMed ID: 16973881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity.
    Wiedemann I; Breukink E; van Kraaij C; Kuipers OP; Bierbaum G; de Kruijff B; Sahl HG
    J Biol Chem; 2001 Jan; 276(3):1772-9. PubMed ID: 11038353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mode of action of lipid II-targeting lantibiotics.
    Bauer R; Dicks LM
    Int J Food Microbiol; 2005 May; 101(2):201-16. PubMed ID: 15862882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.